Parameters favorable to intraprostatic radiation dose escalation in men with localized prostate cancer.
暂无分享,去创建一个
Holly Ning | Aradhana Kaushal | Deborah Citrin | Kevin Camphausen | Peter Choyke | Uma Shankavaram | Barbara Arora | K. Camphausen | P. Choyke | H. Ning | U. Shankavaram | D. Citrin | N. Housri | Nadine Housri | John Ondos | B. Arora | A. Kaushal | John Ondos
[1] R. DiPaola,et al. Contemporary risk profile of prostate cancer in the United States. , 2009, Journal of the National Cancer Institute.
[2] George Starkschall,et al. Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial , 2003 .
[3] Bruno Speleers,et al. Intensity-modulated radiotherapy as primary therapy for prostate cancer: report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion. , 2008, International journal of radiation oncology, biology, physics.
[4] Daniel W. Miller,et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. , 2005, JAMA.
[5] C C Ling,et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. , 2001, The Journal of urology.
[6] Xavier Leroy,et al. Peripheral zone prostate cancers: Location and intraprostatic patterns of spread at histopathology , 2009, The Prostate.
[7] Henning Salz,et al. Dynamic MRI and CAD vs. Choline MRS: Where is the detection level for a lesion characterisation in prostate cancer? , 2009, International journal of radiation biology.
[8] G. Gustafson,et al. Predictors for chronic urinary toxicity after the treatment of prostate cancer with adaptive three-dimensional conformal radiotherapy: dose-volume analysis of a phase II dose-escalation study. , 2007, International journal of radiation oncology, biology, physics.
[9] A. Hanlon,et al. The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer , 2004, Cancer.
[10] Tom W J Scheenen,et al. IMRT boost dose planning on dominant intraprostatic lesions: gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI. , 2006, International journal of radiation oncology, biology, physics.
[11] Intra- and inter-radiation therapist reproducibility of daily isocenter verification using prostatic fiducial markers , 2006, Radiation oncology.
[12] D. Kuban,et al. Effect of local tumor control on distant metastasis and survival in prostatic adenocarcinoma. , 1987, Urology.
[13] C. Reddy,et al. Radiation dose response in patients with favorable localized prostate cancer (Stage T1-T2, biopsy Gleason < or = 6, and pretreatment prostate-specific antigen < or = 10). , 2001, International journal of radiation oncology, biology, physics.
[14] George Starkschall,et al. Late rectal toxicity: dose-volume effects of conformal radiotherapy for prostate cancer. , 2002, International journal of radiation oncology, biology, physics.
[15] S. Webb,et al. Potential improvements in the therapeutic ratio of prostate cancer irradiation: dose escalation of pathologically identified tumour nodules using intensity modulated radiotherapy. , 2002, The British journal of radiology.
[16] M. Eble,et al. Image-guided radiotherapy for prostate cancer , 2008, Strahlentherapie und Onkologie.
[17] D P Dearnaley,et al. Comparison of MRI with CT for the radiotherapy planning of prostate cancer: a feasibility study. , 1999, The British journal of radiology.
[18] Y. Yamada,et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. , 2008, International journal of radiation oncology, biology, physics.
[19] H. Huisman,et al. Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. , 2006, Radiology.
[20] Frederik Wenz,et al. Intrafraction motion of the prostate during an IMRT session: a fiducial-based 3D measurement with Cone-beam CT , 2008, Radiation oncology.
[21] J. McNeal,et al. Patterns of spread of adenocarcinoma in the prostate as related to cancer volume , 2001, The Prostate.
[22] A. D'Amico,et al. Defining the Rectal Dose Constraint for Permanent Radioactive Seed Implantation of the Prostate , 2005 .
[23] A. Zietman,et al. Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] I. Hsu,et al. Proposed rectal dose constraints for patients undergoing definitive whole pelvic radiotherapy for clinically localized prostate cancer. , 2008, International journal of radiation oncology, biology, physics.
[25] M. V. van Herk,et al. Prostate gland motion assessed with cine-magnetic resonance imaging (cine-MRI). , 2005, International journal of radiation oncology, biology, physics.
[26] J. Pouliot,et al. Inverse planning for HDR prostate brachytherapy used to boost dominant intraprostatic lesions defined by magnetic resonance spectroscopy imaging. , 2004, International journal of radiation oncology, biology, physics.
[27] G. Andriole,et al. Influence of Local Tumor Control on Distant Metastases and Cancer Related Mortality After External Beam Radiotherapy for Prostate Cancer , 2008 .
[28] B Pickett,et al. Forward or inversely planned segmental multileaf collimator IMRT and sequential tomotherapy to treat multiple dominant intraprostatic lesions of prostate cancer to 90 Gy. , 2001, International journal of radiation oncology, biology, physics.
[29] L Verhey,et al. Static field intensity modulation to treat a dominant intra-prostatic lesion to 90 Gy compared to seven field 3-dimensional radiotherapy. , 1999, International journal of radiation oncology, biology, physics.
[30] Yoshiya Yamada,et al. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes. , 2008, International journal of radiation oncology, biology, physics.
[31] Leen Paelinck,et al. The magnetic resonance detected intraprostatic lesion in prostate cancer: planning and delivery of intensity-modulated radiotherapy. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[32] F Lohr,et al. [Image-guided radiotherapy for prostate cancer]. , 2007, Aktuelle Urologie.
[33] K. Yamada,et al. Visualization of prostate cancer using dynamic contrast-enhanced MRI: comparison with transrectal power Doppler ultrasound. , 2003, The British journal of radiology.
[34] Gabor Fichtinger,et al. Simultaneous integrated boost of biopsy proven, MRI defined dominant intra-prostatic lesions to 95 Gray with IMRT: early results of a phase I NCI study , 2007, Radiation oncology.
[35] C. Kim,et al. Localization of Prostate Cancer Using 3T MRI: Comparison of T2-Weighted and Dynamic Contrast-Enhanced Imaging , 2006, Journal of computer assisted tomography.
[36] Cedric Yu,et al. Magnetic resonance spectroscopic imaging-guided brachytherapy for localized prostate cancer. , 2001, International journal of radiation oncology, biology, physics.
[37] Vincenzo Valentini,et al. Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: implications for conformal therapy planning. , 2002, International journal of radiation oncology, biology, physics.